Eni SpA vs Stryker Corporation — how do they compare? Eni SpA trades at $56 (market cap $79.81B), while Stryker Corporation trades at $276.85 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Eni SpA pays the higher dividend (4.39%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Stryker Corporation for 20 Days on average.
| E | SYK | |
|---|---|---|
Market Cap | $79.81B | $106.24B |
Volume | 365,912 | 2,982,001 |
Sector | Energy | Health |
52-Week High | $57.61 | $388.35 |
52-Week Low | $34.03 | $269.75 |
Typical Hold Time | 53 Days | 20 Days |
Enterprise Value | $104.34B | $117.70B |
Dividend Yield | 4.39% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $53.96, down 1.08% on the day, amid a bearish technical signal and mixed earnings performance. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97%. Recent news highlights strategic moves in humanoid robotics, LNG projects, and fuel discounts. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85, while cash flow remains positive but net cash flow turned negative in 2026 projections.
The outlook is cautious; low valuations and dividend payments offer value, but revenue declines and earnings misses pose risks. Analyst consensus is mixed with 34.62% buy ratings. Key risks include energy price volatility and execution of new tech initiatives. Further upside depends on stabilizing revenue and meeting earnings expectations.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →